(UK) and Generics (UK) will jointly develop eight generic
dermatological products for the European market. The agreement
covers products, which have current sales of around $225
million, Glenmark informed the BSE in a release.
(UK) is a wholly owned subsidiary of Glenmark Pharmaceuticals
while Generics (UK) belongs to the Merck Generics Group,
a subsidiary of Merck KGaA of Darmstadt, Germany.
will develop, manufacture and supply the products while
both the companies would be responsible for their own
sales and marketing.
first of these products has already been filed and is
targeted to be launched in 2007. The remaining products
are expected to be launched by 2010," the release
are happy to partner with Merck Generics, which, besides
being a well respected global generic pharmaceutical player,
also has a strong sales presence in Europe. Our association
is a testament to Glenmark''s combined strengths in dermatology
and R&D," Glenn Saldanha, MD and CEO of Glenmark
Pharma, said in the release.
commenced its European operations by establishing a wholly
owned subsidiary, Glenmark Pharmaceuticals [UK] Ltd in
2004. Its focus is on developing and marketing niche and
branded generic products. The company is also evaluating
inorganic growth opportunities, including acquisition
of sales and distribution rights in select high-potential
is a research-led, global, fully integrated pharmaceutical
company headquartered in Mumbai the company has generic
formulation and API business interests in over 80 countries,
including the highly regulated markets of the USA and
Europe. The formulation business spans several product
segments covering dermatology, internal medicine, paediatrics,
gynaecology, ENT and diabetes.
company in also engaged in cutting-edge research in discovering
new molecules and runs discovery projects in the areas
of inflammation (Asthma / COPD, etc) and metabolic disorders
(diabetes, obesity, etc). Its first asthma / COPD molecule,
Oglemilast, was licensed out to Forest Laboratories and
Teijin Pharma Limited for the North American and Japanese
markets, respectively. This compound subsequently completed
Phase I clinical trials successfully and has recently
entered Phase II clinical trials in the US. The company''s
second lead GRC 8200, a DPP-IV inhibitor for Type II diabetes,
is in Phase II clinical trials in South Africa.
third lead is a compound named GRC 10389, a CB-I receptor
antagonist for the treatment of obesity. This compound
is completing pre-clinical studies and is expected to
be filed for a Phase I trial in H1 FY07. The company has
three other programmes across inflammation and pain management
at the pre-clinical stages.
part of the Amerpharm Group, Generics (UK) Limited was
acquired by Merck KGaA in 1994. and is now part of the
wider "Merck Generics Group" which comprises
some fifteen companies, including: Alphapharm of Australia,
Merck Generics BV of the Netherlands, Merck Dura of Germany,
Merck Génériques of France, Genpharm of
Canada, Gerard Laboratories of Eire, Scandpharm Generics
of Sweden and Pacific of New Zealand.
KGaA (Merck worldwide) is a major European healthcare
and science based company with interests in ethical and
generic pharmaceuticals, laboratory products and diagnostics
and speciality chemicals. The company operates in 52 countries
and over 28,900 people are employed worldwide. It is listed
on the Frankfurt stock exchange and recorded a turnover
of €5,339.5 billion for the year to December 2004.